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Abstract. 
 
Previous studies have demonstrated that 
NT2N neurons derived from a human embryonal carci-
noma cell line (NT2) constitutively process the endoge-
nous wild-type 
 
b
 
-amyloid precursor protein (APP) to 
amyloid 
 
b
 
 peptide in an intracellular compartment. 
These studies indicate that other proteolytic fragments 
generated by intracellular processing must also be 
present in these cells. Here we show that the NH
 
2
 
-ter-
minal fragment of APP generated by 
 
b
 
-secretase cleav-
age (APP
 
b
 
) is indeed produced from the endogenous 
full length APP (APP
 
FL
 
). Pulse–chase studies demon-
strated a precursor–product relationship between 
APP
 
FL
 
 and APP
 
b
 
 as well as intracellular and secreted 
APP
 
b
 
 fragments. In addition, trypsin digestion of intact 
NT2N cells at 4
 
8
 
C did not abolish APP
 
b
 
 recovered 
from the cell lysates. Furthermore, the production of 
intracellular APP
 
b
 
 from wild-type APP appears to be a 
unique characteristic of postmitotic neurons, since in-
tracellular APP
 
b
 
 was not detected in several non-neu-
ronal cell lines. Significantly, production of APP
 
b
 
 oc-
curred even when APP was retained in the ER/
intermediate compartment by inhibition with brefeldin 
A, incubation at 15
 
8
 
C, or by expression of exogenous 
APP bearing the dilysine ER retrieval motif.
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1. 
 
Abbreviations used in this paper
 
: A
 
b
 
, amyloid 
 
b
 
; AD, Alzheimer’s dis-
ease; APP, amyloid precursor protein; BFA, brefeldin A; CNS, central
nervous system; Endo H, endoglycosidase H; IC, intermediate compart-
ment; Nglyc F, 
 
N
 
-glycosidase F; SFV, Semliki Forest virus.
 
A
 
myloid 
 
b
 
 (A
 
b
 
)
 
1
 
 peptides are the building blocks of
the amyloid fibrils found in neuritic plaques and
vascular deposits that accumulate in the brains of
patients with Alzheimer’s disease (AD; Selkoe, 1994). A
 
b
 
is derived from proteolytic processing of one or more iso-
forms of the amyloid precursor protein (APP; Kang et al.,
1987). APP isoforms are alternatively spliced type I trans-
membrane glycoproteins that are encoded by a single gene
on human chromosome 21 (Kang et al., 1987; St. George-
Hyslop et al., 1987). The 39–43-amino acid-long A
 
b
 
 se-
quence begins in the ectodomain of APP and extends into
the transmembrane region (see Fig. 1). Of the three major
A
 
b
 
-containing isoforms encoded by the APP gene (i.e.,
APP695, APP751, and APP770; Kang et al., 1987; Kitagu-
chi et al., 1988; Ponte et al., 1988; Tanzi et al., 1988),
APP695 is expressed almost exclusively by neurons of the
central and peripheral nervous systems (Golde et al., 1990;
Kang and Müller-Hill, 1990; Arai et al., 1991).
Newly synthesized APP matures in the endoplasmic
reticulum and the Golgi apparatus, acquiring 
 
N
 
- and 
 
O
 
-linked
carbohydrates, tyrosine sulfates (Weidemann et al., 1989;
Oltersdorf et al., 1990), and phosphates (Oltersdorf et al.,
1990; Suzuki et al., 1992; Knops et al., 1993). Several path-
ways of APP metabolism have been described in cultured
cells, and evidence suggests that the relative importance of
each pathway depends on the cell type. For example,
non-neuronal cells preferentially process APP by the
 
a
 
-secretase pathway, which cleaves APP within the A
 
b
 
 se-
quence, thereby precluding the formation of A
 
b
 
 (Esch et
al., 1990; Sisodia et al., 1990). The putative 
 
a
 
-secretase en-
zyme(s) is active at or near the cell surface, causing the
NH
 
2
 
-terminal fragment (APP
 
a
 
) to be quickly secreted. In
contrast, neuronal cells process a much larger portion of
APP by the 
 
b
 
-secretase pathway(s), which generate intact
A
 
b 
 
by the combined activity of two enzyme classes. The
 
b
 
-secretase(s) cleaves APP at the NH
 
2
 
 terminus of the A
 
b
 
domain releasing a distinct NH
 
2
 
-terminal fragment (APP
 
b
 
).
In addition, the 
 
g
 
-secretase(s) cleaves APP at alternative
sites of the COOH terminus, generating species of A
 
b
 
 that
are either 40 (A
 
b
 
40
 
) or 42 amino acids long (A
 
b
 
42
 
; Seubert
et al., 1993; Suzuki et al., 1994; Turner et al., 1996). 
Although the identities of the putative 
 
a
 
-, 
 
b
 
-, and
 
g
 
-secretases remain speculative, and the precise subcellu-
lar localization of their activity is poorly understood, in
vitro studies have suggested the existence of at least two
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b
 
-secretase pathways. In the endosomal/lysosomal path-
way, APP targeted to the cell surface is endocytosed
and delivered to endosomes and lysosomes where 
 
b
 
- and
 
g
 
-cleavages can occur (Golde et al., 1992; Haass et al.,
1992
 
a
 
; Nordstedt et al., 1993; Koo and Squazzo, 1994; Lai
et al., 1995; Perez et al., 1996). The alternative 
 
b
 
-secretory
pathway is predicted to generate A
 
b
 
 in Golgi-derived ves-
icles, most likely secretory vesicles, before secretion
(Haass et al., 1995
 
a
 
; Higaki et al., 1995; Perez et al., 1996;
Thinakaran et al., 1996
 
b
 
). Whether these pathways oper-
ate in the same or different cell types is not known, nor is
the biological importance of each pathway for the produc-
tion of A
 
b
 
 in vivo understood.
Recently, we showed that both A
 
b
 
40
 
 and A
 
b
 
42
 
 are pro-
duced intracellularly from endogenous wild-type APP695
by cultured postmitotic central nervous system (CNS) neu-
ronal cells (NT2N) that are induced to differentiate from a
human teratocarcinoma cell line (NT2) by treatment with
retinoic acid (Pleasure et al., 1992; Pleasure and Lee, 1993;
Wertkin et al., 1993; Turner et al., 1996). To date, the
human-derived NT2N neuron is the only cell line docu-
mented to generate intracellular A
 
b
 
40
 
 and A
 
b
 
42
 
 before
their eventual release into the medium (Turner et al.,
1996). Because neurons are the cell type most adversely
affected by AD, the NT2N neurons represent a unique
system for the study of intracellular 
 
b
 
-secretase pathways
in a human neuronal model. An essential first step in the
analysis of such pathways is the identification of the pro-
teolytic fragments that are the products of these cleavages.
We report here that in addition to A
 
b
 
40
 
 and A
 
b
 
42
 
, the NH
 
2
 
-
terminal fragment generated by 
 
b
 
 cleavage (i.e., APP
 
b
 
) is
produced intracellularly in NT2N neurons before secretion.
More significantly, we demonstrate that novel 
 
b
 
-secretase
activity occurs in the ER/intermediate compartment (IC)
of neuronal cells using inhibition with Brefeldin A (BFA),
incubation at 15
 
8
 
C, and expression of exogenous APP
bearing the dilysine ER-retrieval motif.
 
Materials and Methods
 
Cell Culture
 
NT2 cells derived from a human embryonal carcinoma cell line (Ntera
2/c1.D1) were grown and passaged twice weekly in Opti-Mem (Life Tech-
nologies, Inc., Gaithersburg, MD) supplemented with 5% FBS and peni-
cillin/streptomycin (P/S) as described previously (Pleasure et al., 1992;
Pleasure and Lee, 1993). To begin differentiation, 2.5 
 
3
 
 10
 
6
 
 cells were
seeded in a 75-cm
 
2
 
 (T75) flask and fed with DME HG (Life Technologies,
Inc.) containing 10 
 
m
 
M retinoic acid, 10% FBS, and P/S twice weekly for 5
wk. The cells in a single T75 flask were then replated at a lower density in
2 
 
3
 
 225 cm
 
2
 
 (T225) flasks for 10 d (Replate 1 cells). Greater than 99%
pure NT2N neurons were then obtained by enzymatic treatment and me-
chanical dislodegment of Replate 1 cells and replated at a density of 6 
 
3
 
 10
 
6
 
cells/10-cm dish previously coated with polylysine and Matrigel (Pleasure
et al., 1992). The NT2N neurons were maintained in medium consisting of
one part conditioned medium and one part DME HG containing 10%
FBS and P/S. For experiments involving the incubation of NT2N neurons
at 15
 
8
 
C for 16 h, regular medium containing DME HG and 10% FBS was
replaced by DME HG containing 25 mM Hepes, 10% FBS, and P/S. Cul-
tures of NT2N neurons were used for experiments when they were be-
tween 3 to 4 wk old. CHO695 cells, a gift from Dr. S. Sisodia (Johns Hop-
kins University School of Medicine, Baltimore, MD), were grown and
passaged three times per week in 
 
a
 
-MEM (Life Technologies, Inc.) sup-
plemented with 10% FBS and P/S. M17 cells were grown and passaged
once per week in Opti-Mem (Life Technologies, Inc.) containing 10% iron-
enriched calf serum and P/S.
 
Metabolic Labeling, Gel Electrophoresis, 
Immunoblotting, and Quantitation
 
Cultured NT2N neurons were starved in methionine-free DME HG (Life
Technologies, Inc.) for 30 min before incubation in fresh, methionine-free
DME HG containing 0.5 mCi/ml of [
 
35
 
S]methionine (sp act 1,000 Ci/
mmol; NEN-Du Pont, Boston, MA). For steady-state labeling studies,
NT2N neurons were labeled with [
 
35
 
S]methionine continuously for 16 h.
For pulse–chase studies, cells were labeled with [
 
35
 
S]methionine for 1 h,
washed twice with methionine-containing DME, and then chased in the
same medium for 0 to 24 h. APP
 
FL
 
, APP
 
a
 
, and APP
 
b
 
 were separated on
7.5% Laemmli SDS-PAGE gels, and A
 
b
 
 and p3 were separated on 10/
16.5% step-gradient Tris-tricine gels. These gels were either stained with
Coomassie brilliant blue R (Pierce, Rockford, IL) and dried or transferred
to nitrocellulose membranes and dried before exposure on PhosphorIm-
ager plates (Molecular Dynamics, Sunnyvale, CA) for 3–5 d. The nitrocel-
lulose replicas containing the immunoprecipitates were further probed
with different antibodies, as described previously (Wertkin et al., 1993).
Quantitation of bands in the autoradiogram was performed using the Im-
ageQuant software (Molecular Dynamics) as described previously
(Turner et al., 1996). Radiolabeled proteins in SDS-PAGE gels and nitro-
cellulose replicas were also analyzed by standard autoradiographic meth-
ods. All experiments were repeated between three to six times.
 
Sample Preparation and Serial Immunoprecipitations
 
Cell lysates were prepared as described elsewhere (Golde et al., 1992).
Protein concentration was determined by the bicinchoninic acid proce-
dure (Pierce). Media were centrifuged at 100,000 
 
g
 
 for 1 h at 4
 
8
 
C before
immunoprecipitation. Both cell lysates and media were precleared with
protein A-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) in RIPA
for 1 h at 4
 
8
 
C. After recentrifugation at 15,000 
 
g
 
 for 1 min, the superna-
tants were rocked overnight at 4
 
8
 
C with fresh protein A-Sepharose and
the appropriate primary antibody. After collecting the immunoprecipi-
tates by recentrifugation at 15,000 
 
g
 
 for 1 min, the supernatants were used
in a second round of immunoprecipitation with fresh protein A-Sepharose
and a different primary antibody.
 
Trypsin Treatment of NT2N Neurons
 
NT2N neurons were metabolically labeled with 0.5 mCi/ml [
 
35
 
S]methio-
nine for 16 h, as described above. After rinsing the cultures twice with
PBS, the NT2N neurons were incubated on ice for 20 min with PBS, with 10
 
m
 
g/ml of trypsin in PBS alone (Life Technologies, Inc.), or with 10 
 
m
 
g/ml
trypsin and 0.1% Triton X-100 in PBS. After this treatment, trypsin was
inactivated by the addition of 100 
 
m
 
g/ml soybean trypsin inhibitor. The
cells were then washed with PBS, scraped into cell lysis buffer, and pro-
cessed for immunoprecipitation, as described above.
 
BFA Treatment of NT2N Neurons and Deglycosylation 
of Immunoprecipitated APP
 
b
 
NT2N neurons were pretreated with 20 
 
m
 
g/ml of BFA for 1 h before the
addition of 0.5 mCi/ml of [
 
35
 
S]methionine to the cultures for 16 h in the
absence or presence of BFA. The cell lysates and media were processed
for immunoprecipitation as described above. For deglycosylation of
APP
 
b
 
, the immunoprecipitates containing APP
 
b
 
 were washed twice in so-
dium phosphate buffer (20 mmol/liter, pH 7.2) and boiled for 2 min in 10 
 
m
 
l
of 1% SDS. The samples were then boiled for an additional 2 min after
adding 90 
 
m
 
l of the sodium phosphate buffer with sodium azide (10 mmol/
liter), EDTA (50 mmol/liter), and 
 
n
 
-Octylglucoside (0.5% wt/vol). After
the denaturation step as described, deglycosylation was initiated by the
addition of 2 mU neuraminidase (Arthrobacter; Boehringer Mannheim,
Indianapolis, IN), 2.5 mU 
 
O
 
-Glycosidase (Boehringer Mannheim), and
0.4 U 
 
n
 
-Glycosidase F (Boehringer Mannheim). The samples were then
incubated at 37
 
8
 
C for 18 h, and deglycosylated APP
 
b
 
 was run on 7.5%
SDS-PAGE gels as described above. For endoglycosidase H (Endo H)
sensitivity test, cell lysates and media were immunoprecipitated with
Karen as described. The immunoprecipitates were then recovered in 100 
 
m
 
l
60 mM phosphate buffer, pH 5.7, with 1% SDS. The samples were then
split in half (50 
 
m
 
l each) and incubated with 4 
 
m
 
l Endo H (Boehringer
Mannheim) or vehicle at 378C for 18 h. The samples were then run on
7.5% SDS-PAGE gels as described above.Chyung et al. Ab and APPb in the ER/Intermediate Compartment 673
Antibodies for Immunoprecipitation
and Immunoblotting
The antibodies used in this study and their epitope specificities are sum-
marized in Fig. 1. Briefly, Karen is a goat polyclonal antisera raised to the
large, secreted NH2-terminal fragment of APP, and antibody 53 is a rabbit
polyclonal antisera raised to a synthetic peptide corresponding to the
amino acid sequence SEVKM. Antibody 53 binds specifically to the free
COOH terminus of APPb (Howland et al., 1995). Antibody 369W is a
rabbit polyclonal antiserum raised to a synthetic peptide corresponding to
the last 45 amino acid residues at the COOH terminus of APP and was
generously donated by Dr. Sam Gandy (Cornell University School of
Medicine, New York, NY). Also used in this study were three mAbs to Ab
that are specific for residues 1–17 (6E10; Kim et al., 1988, residues 1–10
(Ban50; Suzuki et al., 1994), and residues 18–25 (4G8; Kim et al., 1988).
Preparation of SFV-bearing pSFV-1(APP695) and 
pSFV-1(APP695DKK)
The dilysine motif was introduced into APP695 by standard PCR site-
directed mutagenesis of pSFV-1(APP695) using primers 59-CGAAAAC-
CACCGTGGAGCTCC TT-39 and 59-TTAACCCGGGCTAGTTCT-
GCTTCTTCTCAAAGAACTTGT-39. The mutation-containing PCR
fragment was isolated by digestion with BsmI and XmaI and then ligated
into pSFV(APP695) to yield pSFV(APP695DKK). All pSFV-1 constructs,
including a pSFV helper plasmid with SFV structural genes, were linear-
ized by digestion with SpeI and then used as a template for RNA synthesis
with SP6 RNA polymerase. Coelectroporation of RNA from the expres-
sion and helper plasmids into BHK cells yielded an infectious, replication-
defective virus that was harvested 24 h later (Liljestrom and Garoff, 1991).
Accurate determination of viral stock titers was made as described else-
where (Cook et al., 1996). For all infection experiments, z1 3 106 NT2N
neurons per 35-mm dish were infected in serum-free medium at a multi-
plicity of infection (MOI) of 7–10. When called for, 20 mg/ml BFA was
added after the completion of the infection step.
Results
NT2N Neurons Exhibit Intracellular
b-Secretase Activity
Our previous studies have demonstrated that NT2N cells
produce intracellular Ab (Wertkin et al., 1993; Turner et al.,
1996). To determine if intracellular APPb (Fig. 1) can also
be recovered from these cells, samples of cell lysate were
immunoprecipitated with Karen (an antiserum raised to
the NH2-terminal region of APP). Then, the presence of
APPb in the immunoprecipitate was determined by immu-
noblot analysis using 53 (a polyclonal antibody specific for
the free COOH terminus of APPb). We found that 53 de-
tects a single band of z95 kD (Fig. 2 a). That this 95-kD
APP fragment is indeed APPb, cleaved at the b-secretase
site, was further substantiated by (a) the inability of 369W,
an antibody specific for the COOH terminus of APP, to
recognize this fragment; (b) the inability of 6E10, an anti-
body specific for the first 10 amino acid residues of Ab, to
detect this fragment; (c) the binding of Karen, an antibody
that recognizes all APP species, to this fragment; (d) the
fact that this intracellular APP fragment is z11–12 kD
smaller than APPFL (Fig. 2 a); and (e) the detection of the
same 95-kD APP fragment using a different antibody
specific for APPb (i.e., 192; Seubert et al., 1992; and data
not shown). To determine if APPb is secreted, media from
Figure 1. Proteolytic processing of APPFL. The diagram depicts APP fragments generated by both the a- and b-secretase pathways. A
large, secreted ectodomain called APPa is generated by the putative a-secretase(s) that cleaves APPFL within the Ab domain. A second
cleavage by the g-secretase(s) releases a subfragment of Ab known as p3. Alternative cleavage by the b-secretase(s) generates a simi-
larly large ectodomain fragment known as APPb. After the subsequent g-secretase cleavage, Ab is released. This schematic also shows
the epitope location of the antibodies used in this study to identify the different proteolytic fragments.
Figure 2. NT2N neurons produce intracellular APPb and Ab. To
demonstrate the presence of APPb, samples of cell lysate and
medium were collected from NT2N cultures and processed for
immunoprecipitation (IP) with Karen, a polyclonal antibody that
recognizes epitopes within the large ectodomain of APP. The
presence of APPb, APPa, APPa/b, and APPFL was detected by
immunoblotting (IB) with the corresponding antibodies (A). To
show that Ab but not p3 is produced intracellularly, NT2N neu-
rons were radiolabeled with [35S]methionine for 16 h. The cell ly-
sate and the medium were then processed for immunoprecipita-
tion with 4G8, a mAb that binds to both Ab and p3, or Ban50, a
mAb that recognizes only Ab (B). Immunoprecipitates of Ab
and p3 were separated by electrophoresis in 10/16.5% step-gradi-
ent Tris-tricine gels. M, mature APPFL; I, immature APPFL.The Journal of Cell Biology, Volume 138, 1997 674
NT2N neurons were again immunoprecipitated with Karen
and subsequently immunoblotted with various antibodies
(Fig. 2 a). We found that APPb was readily detected in the
media of NT2N neurons and that it comigrated with APPb
recovered from the cell lysates. However, as expected,
APPb migrated slightly faster than the product of a-secre-
tase cleavage (APPa), which was also recovered from the
media.
The detection of intracellular APPb and Ab in NT2N neu-
rons is consistent with our view that both b- and g-secretase
activities occur in an intracellular compartment. The ab-
sence of intracellular APPa, however, suggests that the
majority or all of the a-secretase activity occurs at a differ-
ent site. To further confirm that the b-secretase pathway,
but not the a-secretase pathway, occurs inside these cells,
we examined the cell lysate of NT2N neurons for the prod-
ucts of these respective pathways: Ab, which is generated
by b- and g-secretase cleavages; and p3, a product of a- and
g-secretase cleavages. To do this, we immunoprecipitated
the cell lysates of metabolically labeled NT2N neurons
with mAbs that can distinguish between these peptides:
4G8 recognizes both Ab and p3; Ban50, however, binds
only to Ab and not p3 (Fig. 2 b). Our data clearly demon-
strate that Ab, but not p3, is produced intracellularly. The
p3 fragment was not detected in cell lysates even after pro-
longed exposure of the film. By contrast, both Ab and p3
were readily recovered from the media. This observation
supports previous findings that the a-secretase pathway
occurs at or near the plasma membrane (Haass et al.,
1992a, 1995b; Sisodia, 1992).
To determine if the recovery of APPb from the cell ly-
sates reflects its intracellular origin or its association with
the cell surface, we treated cultures of NT2N neurons with
trypsin at 48C. Under such conditions, cell surface-associ-
ated but not intracellular APPb should be proteolyzed.
Fig. 3 shows that a similar amount of APPb was recovered
from NT2N neurons regardless of trypsin treatment (Fig.
3, compare lanes 1 and 2). By contrast, when the NT2N
neurons were treated with trypsin and 0.1% Triton X-100,
intracellular APPb was completely eliminated (Fig. 3, lane
3). This experiment provides evidence that the APPb re-
covered from the NT2N cell lysate is indeed produced in
an intracellular compartment.
Intracellular APPb Derived from Wild-Type APP Is 
Detected Only in Cells with a CNS Phenotype
To determine if other cell types are capable of producing
intracellular APPb, the following cell lines were included
in this study for comparison: (a) retinoic acid-naive NT2
cells, the undifferentiated precursors of the NT2N neurons
that express high levels of the APP751 and APP770 iso-
forms; (b) Chinese hamster ovary (CHO) cells stably trans-
fected with APP695; and (c) human M17 neuroblastoma
cells. Approximately 800 mg of total protein collected in
the cell lysates of each cell type was first immunoprecipi-
tated with Karen and then immunoblotted with either an-
tibody 53 to detect APPb (Fig. 4 a) or Karen to detect all
forms of APP (Fig.4 b). We found that while all four cell
types synthesized similar amounts of APP, the NT2N neu-
ron was the only cell type capable of producing detectable
levels of intracellular APPb (Fig. 4 a). However, both
NT2N neurons and stably transfected CHO cells express-
ing APP695, but neither NT2 cells nor the M17 neuroblas-
toma cells, secreted APPb, raising the possibility that se-
cretion of APPb may be isoform specific. While our data
does not preclude low levels of intracellular b-secretase
activity or faster rate of APPb secretion in these cell lines,
the evidence clearly indicates that the fraction of APP pro-
cessed by b-secretase(s) as well as the subcellular site(s) of
this activity may be strongly cell-type dependent.
NT2N Neurons Produce Intracellular APPb
Before Secretion
The experiments shown in Figs. 2–4 demonstrated that
intracellular APPb can be detected in NT2N neurons. These
data suggest that APPb may be generated inside the cell
before secretion. To demonstrate unequivocally that a pre-
cursor–product relationship exists between intracellular and
secreted APPb, we adopted the following approaches. In
Figure 3. APPb is produced intracellularly in NT2N neurons.
Culture dishes containing .99% pure NT2N cells were metaboli-
cally labeled with [35S]methionine for 16 h. Cells were rinsed
twice with PBS and then incubated on ice for 20 min with PBS
alone (lane 1), with 10 mg/ml trypsin (lane 2), or with 10 mg/ml
trypsin and 0.1% Triton X-100 (lane 3). The cells were processed
for immunoprecipitation with the anti-APPb antibody 53, as de-
scribed in Materials and Methods.
Figure 4. Intracellular APPb is observed only in NT2N neurons.
Samples of cell lysate and medium collected from cultures of NT2N,
NT2, M17, and CHO cells stably expressing APP695 (CHO695)
were processed for immunoprecipitation with the antibody Karen.
The immunoprecipitates were separated by SDS-PAGE gels and
transferred onto nitrocellulose replicas. APPb present in the cell
lysates and the media were detected by immunoblotting with the
anti-APPb antibody 53 (A). After stripping the nitrocellulose
replica in A with 0.1% SDS, the blot was reprobed with Karen to
detect all APP ectodomain species (B).Chyung et al. Ab and APPb in the ER/Intermediate Compartment 675
our first approach, NT2N neurons were washed with fresh
medium, and then the amount of intracellular as well as se-
creted APPb and APPa were measured over an 8-h pe-
riod. This was accomplished by immunoprecipitation of
cell lysates and media with Karen followed by immuno-
blotting with either antibody 53 (for APPb) or 6E10 (for
APPa). As shown in Fig. 5, secreted APPb was first de-
tected in 3 to 5 h, and its accumulation in the medium con-
tinued over the 8-h incubation period. By contrast, APPa
was detected in 1 h, suggesting that APPa is produced at a
faster rate than APPb. As seen with APPb, APPa accu-
mulated in the conditioned media over time. Finally, our
data also show that intracellular APPb is produced consti-
tutively, since a steady state level of APPb is recovered
from NT2N cell lysates prepared from parallel cultures
over a period of 8 h (Fig. 5). These findings are consistent
with the idea of APPb being generated inside NT2N neu-
rons before secretion.
We next employed a pulse–chase paradigm to study more
rigorously the temporal relationship between intracellular
and secreted APPb. To this end, NT2N cultures were
pulsed with [35S]methionine for 1 h and then chased for
different lengths of time (Fig. 6). We found that after 1 h
of chase time, full length APP (APPFL) immunoprecipi-
tated from the cell lysate began to decline, while the intra-
cellular level of APPb continued to increase until 4 h, after
which it also declined (Fig. 6, a and c). This lag in maxi-
mum production of intracellular, radiolabeled APPb sup-
ports the idea that APPb is produced intracellularly from
APPFL by b-secretase cleavage. Finally, the 1-h delay in
the secretion of APPb into the medium as well as the accu-
mulation of this fragment with increasing chase time sup-
ports a temporal relationship between APPb that is pro-
duced intracellularly and APPb that is secreted into the
medium (Fig. 6, b and d). Therefore, we conclude that
APPb is produced in an intracellular compartment in
NT2N neurons before secretion.
Intracellular b-Cleavage in NT2N Neurons Occurs in a 
pre-Golgi Compartment
Since APPb is produced in an intracellular compartment
in NT2N neurons, we sought to identify the subcellular
site(s) of b-secretase cleavage. Therefore, NT2N neurons
were metabolically labeled with [35S]methionine in the pres-
ence or absence of 20 mg/ml BFA (Fig. 7). BFA is a phar-
macological agent that causes a redistribution of the Golgi
Figure 5. NT2N neurons produce intracellular APPb before se-
cretion. Cultures of NT2N neurons were washed and fresh me-
dium was replenished before measuring the amount of intracel-
lular and secreted APPb over an 8-h period. Cell lysate and
medium collected at the times indicated were immunoprecipi-
tated with Karen. The immunoprecipitates were separated by
SDS-PAGE and then transferred onto nitrocellulose membranes.
APPb was identified in immunoblots using the antibody 53. APPa
was detected using the antibody 6E10. APPFL and APPa/b were
recognized by Karen.
Figure 6. Pulse–chase label-
ing demonstrates that intra-
cellular APPb is produced in
an intracellular compartment
before secretion in NT2N
neurons. NT2N neurons
were pulse labeled with
[35S]methionine for 1 h and
chased for 0, 1, 4, 8, and 24 h.
Radiolabeled cell lysates (A)
or media (B) were immu-
noprecipitated sequentially
with antibody 53 (for APPb)
followed by Karen (for APPFL
in the cell lysates and APPa/b
in the media). Radiolabeled
immunoprecipitates were used
to expose PhosphorImager
plates (72 h) or X-ray film (3
wk) for visualization. C and
D summarize the quantitation
of experiments shown in A
and  B. Counts from three dif-
ferent experiments were nor-
malized to percentage of max-
imum  and plotted as shown
(mean  6 standard error).The Journal of Cell Biology, Volume 138, 1997 676
into the ER (Doms et al., 1989; Lippincott-Schwartz, 1989;
Pelham, 1991). In the absence of BFA, APPFL, APPb, and
Ab were recovered from the cell lysates, while APPa,
APPb, and Ab were detected in the media of NT2N neu-
rons (Fig. 7, a–c, lanes 1 and 3). Surprisingly, in the pres-
ence of BFA, not only APPFL but also APPb and Ab con-
tinued to be recovered from NT2N cell lysates (Fig. 7, a–c,
lane 2). The effectiveness of BFA was verified by the fact
that the secretion of APPa, APPb, and Ab into the me-
dium was completely abolished in its presence (Fig. 7, a–c,
lane 4). Furthermore, we found that APPb recovered from
BFA-treated cells (Fig. 7 b, lane 2) migrate with an accel-
erated electrophoretic mobility compared to APPb from
nontreated cells (Fig. 7 b, lane 1), suggesting that this frag-
ment may have been derived from immature APP. Indeed,
the faster mobility of mature APPFL in the presence of
BFA (Fig. 7 a, compare M of lanes 1 and 2) indicates that
this agent blocks APP from acquiring at least some of the
posttranslational modifications. Thus, Ab may be gener-
ated from immature as well as mature forms of APP.
We sought next to determine if incomplete maturation
of APP is indeed the cause of the shift in electrophoretic
mobility of the APPb fragment generated in the presence
of BFA. Therefore, NT2N cells were metabolically labeled
with [35S]methionine in the presence or absence of BFA,
and APPb immunoprecipitated from the cell lysate was in-
cubated with N-glycosidase F (Nglyc F), an enzyme that
removes N-linked carbohydrate chains. As shown, APPb
from BFA-treated NT2N neurons (Fig. 8 a, lane 1) mi-
grated more quickly than APPb recovered from untreated
cells (Fig. 8 a, lane 2). After digestion with Nglyc F, APPb
demonstrated a mobility downshift in SDS-PAGE (Fig. 8
a, compare lanes 2 and 4). However, APPb from BFA-
treated cells (Fig. 8 a, lane 3) still migrated faster than
APPb from nontreated cells (Fig. 8 a, lane 4) despite enzy-
matic removal of all N-linked carbohydrate chains. Thus, the
increased electrophoretic mobility of APPb in the pres-
ence of BFA cannot be accounted for solely by differences
in N-linked carbohydrate processing.
In addition to N-linked glycosylation, however, APP un-
dergoes a variety of posttranslational modifications, in-
cluding the addition of O-linked carbohydrate chains.
Therefore, we removed both N- and O-linked carbohy-
drate chains from immunoprecipitated APPb by simulta-
neous digestion with Nglyc F, O-glycosidase, and neur-
aminidase. As shown, fully deglycosylated APPb (Fig. 8 b,
lane  2) comigrated with APPb recovered from BFA-
treated NT2N neurons (Fig. 8 b, lane 3). Furthermore,
combined BFA inhibition and deglycosylation (Fig. 8 b,
lane 4) did not induce a greater mobility shift than either
of these treatments alone (Fig. 8 b, lanes 2 and 3). Taken
together, these results suggest that APPb generated from
BFA-treated NT2N neurons may represent b-secretase
processing of immature (nonglycosylated) APPFL in a pre-
Golgi compartment.
To further verify that b-secretase cleavage indeed oc-
curs early in the biosynthetic pathway of NT2N neurons,
Figure 7. Intracellular b and g cleavages occur in a pre-Golgi
compartment in NT2N neurons. Cultures of NT2N cells were first
preincubated with 20 mg/ml BFA for 1 h before radiolabeling with
[35S]methionine for 16 h in the continuous presence of 20 mg/ml
BFA. Control cultures were processed similarly, except that BFA
was absent in the medium. Radiolabeled proteins from BFA-
treated and untreated cell lysates and media were immunoprecip-
itated with Karen (for APPFL in the cell lysates and APPa/b in
the media as shown in A), with antibody 53 (for APPb in B), and
with the mAb 6E10 (for Ab in C). Note that APPb and Ab were
recovered in the cell lysate but not in the medium of BFA-treated
cells. (M, mature APPFL; I, immature APPFL.
Figure 8. APPb generated in the presence of BFA is partially
glycosylated. Cultures of NT2N neurons were metabolically la-
beled as in Fig. 7 in the presence or absence of 20 mg/ml BFA.
The cell lysates were then immunoprecipitated with the antibody
53. (A) Samples in lanes 3 and 4 were treated with Nglyc F for 16 h
to remove N-linked sugars, whereas immunoprecipitates in lanes
1 and 2 were treated with the vehicle. (B) Samples in lanes 2 and
4 were deglycosylated with a combination of Nglyc F, neuramini-
dase, and O-glycosidase for 16 h to remove both N- and O-linked
chains (lanes 2 and 4); lanes 1 and 3 represent samples that were
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we employed an alternative nonpharmacological method
to block protein transport from the ER to the Golgi. Incu-
bation of cultured cells at 158C has been shown to inhibit
newly synthesized proteins from exiting the intermediate
compartment (Saraste and Kuismanen, 1984; Saraste et al.,
1986; Schweizer et al., 1990). To this end, NT2N cells were
incubated at 158C for 16 h. Fig. 9 a shows that only the im-
mature form of APPFL was present after a 16-h incubation
at 158C, as indicated by its sensitivity to Endo H digestion,
suggesting that it is not transported to the Golgi apparatus
under these conditions (Fig. 9 a, lanes 3 and 4). By con-
trast, incubation of the NT2N cells at 378C yielded both
immature and fully processed APPFL (Fig. 9 a, lanes 1 and
2). As expected, the immature APPFL was Endo H sensi-
tive, while the mature forms of APPFL, having acquired
posttranslational modifications after exiting the ER, were
Endo H resistant. In addition, secreted forms of APP were
not detected in cells maintained at 158C, further substanti-
ating the effectiveness of the temperature block. Signifi-
cantly, continuous production of intracellular APPb was
observed at 158C, despite the fact that the secretion of
APP ectodomain is completely abolished (Fig. 9 b). Taken
together, these data support the ER/IC of NT2N neurons
as a b-cleavage site.
A third approach was adopted to confirm that b-secre-
tase cleavage indeed occurs in a pre-Golgi compartment of
NT2N neurons. To accomplish this, we compared the pro-
cessing of wild-type APP695 and APP695 bearing an ER-
retrieval motif (APP695DKK; Jackson et al., 1990, 1993) in
the NT2N cells. We used recombinant Semliki Forest virus
(SFV) vectors to express APP695DKK, in which the third
and fourth amino acids from the COOH terminus of APP
are changed to lysines (i.e., APP695DKK). Our previous
studies have shown that despite high levels of SFV-medi-
ated APP expression, SFV-infected NT2N cells display a
high degree of fidelity in processing APP (Wertkin et al.,
1993; Turner et al., 1996; Cook et al., 1997). Furthermore,
we have found that cytopathic effects of SFV infection in
NT2N cells as measured by LDH release do not develop
until .48 h after infection (data not shown). Importantly,
all if not a significant majority of APP695DKK colocalize
with calnexin, the ER marker, by immunofluorescence
upon expression in NT2N neurons (Cook et al., 1997).
To determine whether or not APPb can be produced
from APP695DKK, wild-type APP695 and APP695DKK were
separately expressed in NT2N neurons by infection with
SFV vectors bearing these constructs. After infection, du-
plicate wells containing wild-type APP695-infected cells were
also treated with 20 mg/ml BFA. The [35S]methionine-
labeled cell lysates and the media were then sequentially
immunoprecipitated with the antibodies 53 and Karen.
Only the immature form of APPFL was detected from cells
expressing APP695DKK (Fig. 10 b, compare lanes 1 and 3).
Significantly, intracellular production and secretion of
APPb was not affected by genetic targeting of APP to the
ER (Fig. 10 a, lanes 3 and 6). Furthermore, we found that
unlike inhibition with BFA that eliminates transport of all
proteins from the ER to the Golgi, specific retrieval of full
Figure 9. APPb is generated
in the ER/IC of NT2N neu-
rons. Approximately 6 3 106
NT2N neurons were incu-
bated at either 158 or 378C
for 16 h. The cell lysates and
media were harvested and
immunoprecipitated with Ka-
ren. (A) The immunoprecipi-
tates were then split, and half
of the samples was treated
with Endo H for 18 h, while
the other half was mock di-
gested. Subsequent to this
step, the immunoprecipitates
were separated by SDS-
PAGE,  transferred onto ni-
trocellulose replicas, and
probed with the antibody
Karen. The following obser-
vations serve to verify the ef-
fectiveness of the tempera-
ture block: (a) immature
forms of APPFL (I and I9) in
the cell lysate retain Endo H
sensitivity at 158C; (b) ma-
ture glycosylated forms of
APPFL (M) in the cell lysate are not detected at 158C; and (c) secreted fragments are not detected in the conditioned medium at 158C.
(B) Immunoprecipitates were separated by SDS-PAGE, transferred onto nitrocellulose replicas, and probed with antibody 53. APPb
continued to be produced intracellularly despite the effective temperature block. However, secreted APPb was not detected in the me-
dium at 158C. Note that splitting intracellular APPb samples recovered at 158C for Endo H digestion decreased the yield to below the
level of detection by this assay (data not shown). M, mature APPFL; I, immature APPFL; I9, immature APPFL demonstrating a mobility
shift due to Endo H sensitivity.The Journal of Cell Biology, Volume 138, 1997 678
length APP695DKK to the ER allowed the APPb fragment
generated in the ER/IC to be transported to the Golgi
complex for modification before secretion (Fig. 10 a, com-
pare lanes 2 and 3 and lanes 5 and 6). This suggests that
once the ER retention motif is cleaved from the APPb
fragment, it can then be transported to the Golgi complex
for further maturation and subsequent secretion.
Discussion
APP serves as a substrate for a variety of proteolytic pro-
cessing pathways, only some of which result in the produc-
tion of Ab (Selkoe, 1994). However, Ab is the major com-
ponent of senile plaques in the AD brain. Moreover,
mutations in the APP gene associated with Familial Alz-
heimer’s disease alter APP processing and Ab production
in vitro (Citron et al., 1992; Cai et al., 1993; Suzuki et al.,
1994). Thus, it will be important to determine the pro-
teolytic events that lead to Ab production and to identify
the proteases responsible for each step as well as the sites
of their action. In addition, it will be important to consider
the cell type in which these processes occur. Non-neuronal
cells favor the nonamyloidogenic a-secretase pathway. By
contrast, neuronal cells exhibit increased b-secretase activ-
ity (Busciglio et al., 1993; Wertkin et al., 1993). To better
understand APP processing in neurons, we have used the
NT2N system for this study. We have previously shown
that NT2N neurons express the isoform of APP expressed
almost exclusively in the CNS (i.e., APP695) and that they
constitutively produce intracellular and secreted Ab. In
this study, we have identified and characterized some of
the intracellular b-secretase activities that cleave on the
NH2 terminus side of Ab by using specific antibodies to
APPb and to other proteolytic fragments. More signifi-
cantly, however, we have used three independent approaches
to document novel b- and g-secretase activities that occur
in a pre-Golgi compartment.
Several lines of evidence presented here demonstrate
that APPb is derived from APPFL within the cell before se-
cretion. First, APPb was recovered from NT2N cell lysates
even after intact NT2N neurons were treated with trypsin.
Such treatment would eliminate cell surface-associated
APPb but not intracellular APPb. Indeed, the loss of
APPb after trypsin treatment of detergent-permeabilized
NT2N neurons further confirms the intracellular origin of
APPb in NT2N neurons. Second, the continuous presence
of steady state levels of APPb in NT2N neurons, together
with a delay in the detection of APPb in freshly replen-
ished medium, suggested that APPb is generated intracel-
lularly before secretion. Third, pulse–chase experiments
demonstrated that the turnover of intracellular APPb lags
behind the turnover of newly synthesized APPFL, thereby
confirming that APPb is generated from APPFL inside
NT2N neurons before secretion.
The detection of APPb in the cell lysate of NT2N neu-
rons, together with the presence of Ab40 and Ab42 (Turner
et al., 1996), firmly established that an intracellular b-secre-
tase pathway(s) must exist in these cells. At present, no
other cell line has been reported to produce detectable lev-
els of intracellular APPb from endogenous or over-expressed
wild-type APP (Seubert et al., 1993; Haass et al., 1995a;
Thinakaran et al., 1996b). Only human kidney 293 cells
stably transfected with APPsw cDNA yield the related
APPbsw fragment from the cell lysates (Haass et al., 1995a;
Martin et al., 1995). In these non-neuronal cells, however,
treatment with BFA completely eliminates APPbsw and
Ab production (Haass et al., 1995a; Martin et al., 1995; Es-
salmani et al., 1996). In contrast, NT2N neurons continue
to produce APPb and Ab during treatment with BFA, im-
plying that the subcellular site(s) of the b-secretase path-
way is cell-type specific. Furthermore, this lack of inhibi-
Figure 10. APPb is gener-
ated from APPFL that is con-
centrated in the ER. NT2N
cultures of z1 3 106 cells
were infected with recom-
binant SFV containing ei-
ther wild-type APP695 or
APP695DKK constructs. The
dilysine motif concentrates
APPFL to the ER by an effi-
cient retrieval mechanism.
Duplicate cultures infected
with wild-type APP695 were
treated with 20 mg/ml BFA
for comparison. Under these
conditions, the cells were
metabolically labeled with
[35S]methionine for 16 h. Ra-
diolabeled cell lysates and
media were then immuno-
precipitated with antibody 53
(for  APPb,  A) and Karen
(for APPFL and APPa/b, B).
Radiolabeled immunopre-
cipitates were used to expose PhosphorImager plates (72 h) for visualization of bands. Unlike APPb produced under BFA inhibition,
APPb derived from APP695DKK was modified and secreted into the medium.Chyung et al. Ab and APPb in the ER/Intermediate Compartment 679
tion of APPb and Ab production by BFA in NT2N cells
suggests that at least one of the b-secretase pathways is lo-
calized to the ER/IC. Two additional independent means of
testing this hypothesis (i.e., the use of 158C temperature
block and expression of APP bearing the dilysine ER re-
trieval signal) yielded consistent results.
Our data also suggest that the b-secretase pathway, but
not the a-secretase pathway, occurs inside NT2N neurons.
This view is based on the absence of APPa and p3 frag-
ments in NT2N cell lysates. Of course, this observation
alone cannot rule out the possibility of their presence be-
low the level of detection by our assay. Nevertheless, these
results imply that at least in this regard, NT2N neurons are
similar to almost all other cell lines in which the enzymes
of the a-secretase pathway are active at or near the cell
surface. The uniqueness of intracellular processing in post-
mitotic neuronal cells such as the NT2N neurons lies in
the fact that unlike non-neuronal cells, the amyloidogenic
b-secretase pathway(s) is preferred. Accordingly, the level
of Ab secretion is much higher than that of p3 in postmi-
totic NT2N neurons.
The effect of the Swedish mutation on APP processing
is interesting. Overexpression of APPsw in transfected,
non-neuronal cells results in a 5–10-fold increase in Ab se-
cretion (Citron et al., 1992; Cai et al., 1993). Concomitant
with this change, intracellular APPbsw is also detected in
non-neuronal cells stably transfected with APPsw (Haass
et al., 1995a; Thinakaran et al., 1996b). Transfection of wild-
type APP695 in non-neuronal cells, however, fails to pro-
duce intracellular APPb and results in the secretion of
more p3 than Ab (Thinakaran et al., 1996b). Thus, it ap-
pears that the introduction of the Swedish mutation shifts
APP processing away from the a-secretase pathway to the
b-secretase pathway. However, unlike NT2N neurons that
may use multiple b-secretase pathways to produce both in-
tracellular Ab and APPb, APPsw expressing non-neu-
ronal cells use primarily the endosomal/lysosomal path-
way or the Golgi-derived vesicles to generate intracellular
Ab and APPbsw, since treatment of these cells with BFA
completely inhibits APPbsw and Ab production (Haass et
al., 1995a; Martin et al., 1995).
In view of the foregoing, three potential b-secretase
pathways have been identified to date. Of these three, the
endosomal/lysosomal pathway, which processes APP tar-
geted to the cell surface after its reinternalization into en-
dosomes and lysosomes, is the most ubiquitous. Both pri-
mary cultures of neuronal and non-neuronal cells, as well
as multiple cell lines, use this pathway to produce Ab.
However, the contribution of endosomal/lysosomal pro-
cessing to the overall production of Ab is relatively minor
since non-neuronal cells transfected with wild-type APP
produce mostly p3 and very little Ab (Haass et al., 1992a,
b; Koo and Squazzo, 1994; Lai et al., 1995; Thinakaran et al.,
1996b). In contrast, an alternative b-secretase pathway
that produces Ab in Golgi-derived vesicles is the most im-
portant for the production of Ab in cells transfected with
APPsw. Consistent with this view, transfection of an
APPsw construct lacking the cytoplasmic tail, which elimi-
nates reinternalization of cell surface APPsw, does not re-
duce the secretion of Ab (Haass et al., 1995a; Essalmani et
al., 1996). It is likely that the neuron-like NT2N cells also
use this b-secretase pathway since neuronal cells (including
hippocampal neurons and NT2N neurons) produce much
higher levels of Ab than p3. Finally, the third b-secretase
pathway localized to the ER/IC appears to be preferen-
tially used by postmitotic neuronal cells, since intracellular
APPb was not detected in several non-neuronal cell lines
when treated with BFA.
The possibility of Ab generation in the ER of NT2N
neurons identifies these cells as a unique system in which
to test the hypothesis that amyloidogenic processing of
APP within that compartment plays an important role in
the pathogenesis of AD. There is now strong evidence that
mutations in both the APP gene and the recently identi-
fied presenilin genes cause AD by altering APP processing
in ways that lead to the production of more amyloidogenic
form of Ab (i.e., Ab42; Scheuner et al., 1996). Recently, in
both non-neuronal and neuronal cells (including the
NT2N neurons used in this study), the presenilin proteins
have been localized to the ER (Cook et al., 1996; Kovacs
et al., 1996; Thinakaran et al., 1996a). Thus, the identifica-
tion of amyloidogenic processing that may occur within
the ER of neurons raises the formal possibility that direct
or indirect interaction may occur between the presenilins
and APP. Furthermore, the mutations in the presenilin
genes may alter this interaction in a manner that leads to
increased production of Ab42. Therefore, it will be particu-
larly interesting to examine the effects of both Familial
Alzheimer’s disease-linked mutations occurring in the
APP as well as the presenilin genes on the processing of
APP in the ER.
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